~~<i id='6BCADE82B1'><strike id='6BCADE82B1'><tt id='6BCADE82B1'><pre id='6BCADE82B1'></pre></tt></strike></i>~~

Home» Wikipedia» leisure time

leisure time

author：focus 2025-10-02 00:22:38 Page View：4519

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approves Eli Lilly ulcerative colitis treatment Omvoh
Next article： Sports medicine is finally prioritizing gender equality

explore

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Readout Newsletter: XBI biotech index, Akero Therapeutics

Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Sea level rise could wash away turtle breeding grounds around the world, researchers say

1:14AseaturtleisseenatSeaTurtlesResearchRescueandRehabilitationCenterinMugla,TurkeyonAug.18,2021.Seb